Oncology
Video: Improving Prevention of Moderate to Severe Dermatologic Adverse Events in EGFR-Mutant Advanced NSCLC Treated With First-Line (1L) Subcutaneous (SC) Amivantamab + Lazertinib: First Results From a New COCOON Cohort
Connect with us
Connect with us
Would you like to clear and leave your conversation? Message history will be lost.